Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439061 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL31159576 | 0.82 | CYP3A4 (0.48) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL262306 | 0.80 | ALDH1A1 (0.56) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL356846 | 0.80 | TSHR (0.40) | ALDH1A1CYP3A4TSHRMAPK1POLB | |
| SCHEMBL28186183 | 0.79 | CYP3A4 (0.43) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL5160048 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL15778376 | 0.78 | ALDH1A1 (0.55) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| SCHEMBL30006601 | 0.77 | CYP3A4 (0.38) | ALDH1A1CYP3A4TSHRMAPK1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL2045015 | 0.77 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TSHRTDP1MAPK1 | |
| Hydrochloric Acid SCHEMBL8643161 | 0.77 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TSHRTDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| EP-4698517-A1 | <SUP2/>? <SUB2/>?4?NOVEL COMPOUNDS AS ?? <NS1:SUB>7</NS1:SUB>?INHIBITORS | Evotec International GmbH (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-12225748-B2 | Light-emitting element, display device, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-02-11 | — | — | US | disclosed |
| US-20240397738-A1 | Light-Emitting Element, Display Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024218058-A1 | NOVEL COMPOUNDS AS α4β7 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2024-10-24 | — | — | WO | disclosed |
| US-20240292646-A1 | Light-Emitting Element, Display Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| US-11974445-B2 | Light-emitting element, display device, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-04-30 | — | — | US | disclosed |
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2004073634-A2 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-6774235-B2 | HAVING HIV REPLICATION INHIBITING PROPERTIES. | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-10 | — | — | US | disclosed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | disclosed |
| US-6372729-B1 | TREATMENT OF VIRAL DISEASES SUCH AS AIDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-16 | — | — | US | disclosed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | disclosed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | disclosed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | disclosed |
| US-4418208-A | EXTERNAL IMAGING OF THE HEPATOBILIARY SYSTEM | E. R. SQUIBB & SONS, INC. (US) | 1983-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | ALDH1A1 3722/4885CYP3A4 174/4885TSHR 656/4885 |
| US-20240397738-A1 | Light-Emitting Element, Display Device, Electronic Device, and Lighting Device | EHD1, ESR1, EPHX1 | ALDH1A1 1715/4885CYP3A4 466/4885TSHR 3985/4885 |
| US-11974445-B2 | Light-emitting element, display device, electronic device, and lighting device | EHD1, ESR1, EPHX1 | ALDH1A1 1715/4885CYP3A4 466/4885TSHR 3985/4885 |
| US-12225748-B2 | Light-emitting element, display device, electronic device, and lighting device | EHD1, ESR1, EPHX1 | ALDH1A1 1715/4885CYP3A4 466/4885TSHR 3985/4885 |
| US-20240292646-A1 | Light-Emitting Element, Display Device, Electronic Device, and Lighting Device | EHD1, ESR1, EPHX1 | ALDH1A1 1715/4885CYP3A4 466/4885TSHR 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.